Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Aslam, Hannan
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer	Recruiting	1/2	180	Europe, US	LAVA-1207, LAVA-1207 plus Pembrolizumab	Lava Therapeutics, Merck Sharp & Dohme LLC	Metastatic Castration Resistant Prostate Cancer	04/27	04/27